Effects of tibolone or continuous combined oestradiol/norethisterone acetate on glucose and insulin metabolism

Clinical Endocrinology

Volumn 78, Issue 2, 2013, Pages 297-302

  Manassiev, Nik ^a   Godsland, Ian F ^b   Proudler, Anthony J ^c   Whitehead, Malcolm I ^d   Stevenson, John C ^e  

^a Goodrest Croft Surgery   (United States)

^b ST MARY S HOSPITAL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d Portland Hospital   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; ESTRADIOL; GLUCOSE; INSULIN; KLIOFEM; NORETHISTERONE ACETATE; PLACEBO; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; INSULIN METABOLISM; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; BLOOD GLUCOSE; C-PEPTIDE; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES;

EID: 84872104210     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04491.x     Document Type: Article

References (30)

1. Kloosterboer, H.J., (2001) Tibolone: a steroid with tissue-specific mode of action. Journal of Steroid Biochemistry and Molecular Biology, 76, 231-238.
2. Reed, M.J., &, Kloosterboer, H.J., (2004) Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas, 48 (Suppl 1), S4-S6.
3. Milner, M.H., Sinnott, M.M., Cooke, T.M., et al,. (1996) A 2-year study of lipid and lipoprotein changes in postmenopausal women with Tibolone and Estrogen-progestin. Obstetrics and Gynecology, 87, 593-599.
4. Rymer, J., Crook, D., Sidhu, M., et al,. (1993) Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinologica, 128, 259-262.
5. Kloosterboer, H.J., Benedek-Jazsmann, L.J., &, Kicovic, P.M., (1990) Long-term effects of Org OD14 on lipid metabolism in postmenopausal women. Maturitas, 12, 37-42.
6. Bjarnason, N.H., Bjarnason, K., Haarbo, J., et al,. (1997) Tibolone: influence on markers of cardiovascular disease. Journal of Clinical Endocrinology and Metabolism, 82, 1752-1756.
7. Reaven, G.M., (1988) Role of insulin resistance in human disease. Banting Lecture 1988. Diabetes, 37, 1595-1607.
8. Muoio, D.M., &, Newgard, C.B., (2008) Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in Type 2 diabetes. Nature Reviews. Molecular Cell Biology, 9, 193-205.
9. Després, J.-P., Lamarche, B., Mauriège, P., et al,. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine, 334, 952-958.
10. Livingstone, C., &, Collison, M., (2002) Sex steroids and insulin resistance. Clinical Science, 102, 151-166.
11. Manassiev, N.A., Godsland, I.F., &, Crook, D., (2002) Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women. Maturitas, 42, 233-242.
12. Bergman, R.N., Ider, Y.Z., Bowden, C.R., et al,. (1979) Quantitative estimation of insulin sensitivity. American Journal of Physiology, 236, E667-E677.
13. Godsland, I.F., Agbaje, O.F., &, Hovorka, R., (2006) Evaluation of nonlinear regression approaches of estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. American Journal of Physiology. Endocrinology and Metabolism, 291, 167-194.
14. Watanabe, R., Vølund, A., Roy, S., et al,. (1989) Prehepatic beta-cell secretion during the intravenous glucose tolerance test in humans: application of a combined model of insulin and C-peptide kinetics. Journal of Clinical Endocrinology and Metabolism, 69, 790-797.
15. Morin-Papunen, L.C., Vauhiconen, I., Ruokonen, A., et al,. (2004) Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: a randomised study. European Journal of Endocrinology, 150, 705-714.
16. Christodoulakos, G., Lambrinoudaki, I., Panoulis, C., et al,. (2005) Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Maturitas, 50, 321-330.
17. Wiegratz, I., Storflinger, F., Tetzloff, W., et al,. (2002) Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas, 41, 133-141.
18. Odmark, I.-S., Carlstom, K., Jonsson, B., et al,. (2006) Conjugated estrogen/progestogen versus tibolone hormone replacement therapy in postmenopausal women: effects on carbohydrate metabolism and sex hormone binding globulin. Maturitas, 53, 89-96.
19. Osmanagaoglu, M., Osmanagaoglu, S., Osmanagaoglu, T., et al,. (2005) Effects of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertility and Sterility, 84, 384-393.
20. Godsland, I.F., Gangar, K.F., Walton, C., et al,. (1993) Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism, 42, 846-853.
21. Spencer, C.P., Godsland, I.F., Cooper, A.J., et al,. (2000) Effects of oral and transdermal 17 beta-oestradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion and elimination in postmenopausal women. Metabolism, 49, 742-747.
22. Kimmerle, R., Heinemann, L., Heise, T., et al,. (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause, 6, 36-42.
23. Kenemans, P., (2004) Tibolone: how does its mechanism of action translate into clinical effect. Maturitas, 48 (Suppl 1), S1-S3.
24. Kloostenboer, H.J., (2004) Tissue-selectivity: the mechanism of action of tibolone. Maturitas, 48 (Suppl 1), S30-S40.
25. Dunaif, A., (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocrine Reviews, 18, 774-800.
26. Mauras, N., Welch, S., Rini, A., et al,. (1998) Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole body protein metabolism in post-pubertal young females: a metabolic study. Journal of Clinical Endocrinology and Metabolism, 83, 1900-1905.
27. Zanolin, E.M., Tosi, F., Zoppini, G., et al,. (2006) Clustering of cardiovascular risk factor associated with the insulin resistance syndrome. Assessment of principal component analysis in young hyperandrogenic women. Diabetes Care, 29, 372-378.
28. Escobar-Morreale, H.F., Luque-Ramirez, M., &, San Milan, J.L., (2005) The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews, 26, 251-282.
29. Moghetti, P., Tosi, F., Castelo, R., et al,. (1996) The insulin resistance in women with hyperandrogenism is partially reversed by anti-androgen treatment: evidence that androgens impair insulin action in women. Journal of Clinical Endocrinology Metabolism, 81, 952-960.
30. Kajaia, N., Binder, H., Dittrich, R., et al,. (2007) Low sex-hormone binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. European Journal of Endocrinology, 157, 499-507.